Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation CDK inhibitors for the treatment ... and development cost of each new drug by 20%. Roche will “fast ...

We have seen this previously with CDK4/6 inhibitors where improved selectivity, compared to first generation CDK inhibitors, was key to achieving a therapeutic profile to gain approval,” says ...

A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Pfizer’s CDK inhibitor early-stage pipeline leverages next-generation molecules that are ... Pfizer will continue to take bold new approaches to breast cancer research and development with ...

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle ... macrocycle cyclin A/B RxL inhibitor, has been selected for ...

--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation ... cancer following CDK 4/6-inhibitor therapy.

In the study, published in Molecular Oncology, the researchers describe the activity of CCT068127 which was developed from seliciclib, an early-generation CDK-inhibiting drug. The new inhibitor has ...

Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation CDK inhibitors for the treatment of breast ... Roche plans to cut the research and development cost of each new ...

In the study, published in Molecular Oncology, the researchers describe the activity of CCT068127 which was developed from seliciclib, an early-generation CDK-inhibiting drug. The new inhibitor has ...